Researchers identify protein linked to tumor invasion

June 24, 2002

BOSTON - A protein known for its role in helping to provide the body's immune system with a line of defense against infection has unexpectedly been discovered in cancer cells that were removed from aggressive carcinomas of the breast and colon.

This discovery, reported in the June 24 on-line issue of Nature Cell Biology, could provide scientists with a promising new target for the development of a drug to halt tumor invasion and metastasis, the spread of cancer from its primary site to other areas of the body.

Metastasis occurs when cancer cells penetrate the boundaries of the tumor's tissue and infiltrate the walls of blood vessels or lymph vessels, gaining a means of transport to other parts of the body - far from the original tumor site - where they can then grow anew. This process is unique to cancer cells and is what makes the disease so dangerous - and so feared.

"A primary [cancerous] tumor can be removed," explains the study's senior author Alex Toker, Ph.D., of the department of pathology at Beth Israel Deaconess Medical Center (BIDMC) and assistant professor at Harvard Medical School. "But once the cancer has metastasized, it becomes intractable." In fact, the goal of early cancer detection is to remove the primary carcinoma before it has a chance to spread.

Scientists have known that in order for a tumor to metastasize, certain genes had to be "turned on" so that they could produce enzymes necessary to invade blood vessel walls and penetrate other tissues. Toker and his coauthors at BIDMC and at the Center for Blood Research at Harvard Medical School, set out to identify how this was happening, and began by focusing on the actions of a group of proteins known as transcription factors, including NFAT (nuclear factor of activated T cells).

NFAT, which is critical for efficient immune cell responses, was first identified in the cells of the immune system about 20 years ago. It subsequently became the target for cyclosporin A, a drug used to suppress the immune systems of patients undergoing organ transplants in order to prevent their bodies from rejecting their new organs. NFAT has also been shown to be important for heart development during embryogenesis.

In this new study, lead author Sebastien Jauliac, Ph.D., was surprised to find high levels of NFAT in cancer cells. In order to evaluate the contribution of NFAT to tumor metastasis, the authors used laboratory models of cancer cell invasion. Their results showed that the protein NFAT was indeed contributing to the aggressive, invasive behavior of cancer cells.

Because there was no information indicating NFAT expression in human metastatic cancer, the researchers evaluated the presence of NFAT in tissue samples from five breast cancer patients with aggressive grade III ductal carcinoma, who had positive lymph node metastases at the time of diagnosis.

Besides showing a high correlation between tumor aggression and NFAT levels, the researchers showed that NFAT is found in association with another protein, the alpha 6 beta 4 integrin. This integrin has been linked with several hallmarks of metastatic tumors, including epithelial cell motility, cellular survival and carcinoma invasion.

According to Toker, the next step for researchers will be to attempt to determine the subset of genes that are induced by the NFAT proteins in invasive tumors, and to assess the importance of these genes to the process of metastasis.

"Cancer has been attacked from a large number of fronts, but this discovery presents a previously unappreciated role for NFAT in human cancer," says Toker. "If we pursue this avenue, and add NFAT to the growing list of proteins that have been shown to be important for disease progression, we could be offering a novel target for drug discovery to block this aspect of cancer progression. We may be providing another weapon in our arsenal in the fight against cancer."
Study co-authors include Sebastien Jauliac, Ph.D., Leslie Shaw, Ph.D., and Lawrence Brown, M.D., of Beth Israel Deaconess Medical Center; and Cristina Lopez-Rodriguez, Ph.D., and Anjana Rao, Ph.D., of the Department of Pathology and Center for Blood Research, Harvard Medical School.

This research was funded by grants from the National Institutes of Health (NIH) and the U.S. Department of Defense, and by fellowships from the Association Pour la Recherche Contre le Cancer, the Cancer Research Institute and the Leukemia and Lymphoma Society.

Beth Israel Deaconess Medical Center is a major patient care, research and teaching affiliate of Harvard Medical School and a founding member of CareGroup Healthcare System. Beth Israel Deaconess is the third largest recipient of NIH Research funding among independent U.S. teaching hospitals.

Beth Israel Deaconess Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to